Company Overview and News
TORONTO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ; OTCQX:TGCDF) will release its third quarter 2018 financial and operating results on Thursday, November 1, 2018 at approximately 6:00 a.m. ET. A conference call and webcast hosted by management will follow at 8:30 a.m. ET to review the Company’s results and discuss the quarter’s highlights.
Above are two quality gold producers. I have selected them as the current best risk/reward gold producers. These two stocks should outperform the price of gold significantly - if it rises. In fact, I expect these stocks to double in value if gold reaches $1,500. These are the stocks that you want to own if you are looking for high returns - if gold prices start trending higher.
TGZ ARNGF AR TGZ
TORONTO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ; OTCQX:TGCDF) is pleased to announce that it is acquiring the remaining 49% interest in the Golden Hill and Gourma projects from Boss Resources Limited (“Boss”) (ASX:BOE) for a total of AUD10 million.
TGZ BOE TGZ
TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX: TGZ; OTCQX:TGCDF) is pleased to announce the results of an updated mineral reserve estimate and feasibility study for the Wahgnion development project in Burkina Faso, West Africa.
TGZ MALRY MALRF MIN TGZ
2018-09-20 globenewswire - 1
TORONTO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ; OTCQX:TGCDF) is pleased to announce that the most recent diamond drill program results on its Golden Hill property in Burkina Faso, West Africa have returned strong near surface, oxide zone and deeper gold intersections at a number of advanced prospects. The latest drill results from the C-Zone, Ma North, Peksou and Jackhammer Hill prospects have also expanded mineralization along trend and to depth.
TGZ BOE TGZ
Sabodala is well on track to produce at least 230,000 ounces of gold1 in 2018, Wahgnion is expected to add more than 350,000 ounces to mineral reserves, and Golden Hill initial resource to be released in January
TGZ TGCDF TGZ
Good morning and welcome to Teranga Gold’s conference call for the 3 and 6 month periods ended June 30, 2018. As a reminder, this conference call is being recorded. Your host for today is Trish Moran, Head of Investor Relations. Ms. Moran, please go ahead.
TGZ BOE TGZ
TORONTO, July 16, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ) (OTCQX:TGCDF) will release its second quarter 2018 financial and operating results on Thursday, August 2, 2018 at approximately 6:00 a.m. ET. A conference call and webcast hosted by management will follow at 8:30 a.m. ET to review the Company’s results and discuss the quarter’s highlights.
Boss Resources Ltd (ASX:BOE) has hit near-surface and deeper gold intersections during drilling at three prospects within its Golden Hill property in Burkina Faso.
TGZ BOE TGZ
TORONTO, July 12, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ) (OTCQX:TGCDF) is pleased to announce that its most recent diamond drill program on the Golden Hill property in Burkina Faso, West Africa has returned near surface and deeper gold intersections that will enhance resources at a number of advanced prospects. In addition, the recent drilling evaluation program identified a new near-surface discovery at Peksou North, one of 9 prospects drilled at Golden Hill over the past 18 months.
TGZ BOE TGZ
TORONTO, June 07, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation (“Teranga” or the “Company”) (TSX:TGZ) (OTCQX:TGCDF) is pleased to announce an updated mineral resource estimate for its Wahgnion gold development project (“Wahgnion”) in Burkina Faso, West Africa.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...